Saccharo: Funding, Investors & Team (Sep 2026)
Saccharo is a biotech start-up in the immuno-oncology space that develops therapeutic products for the treatment of cancer and other novel diseases. Saccharo discovered a polysaccharide that surrounds human cancer cells. The Sacchario approach has a mechanism of action that allows drugs to have multiple killing effects, a predicted safety profile, a broad therapeutic window, and applications to many cancers. Saccharo was established in 2017 by Sherry Martin-Moe and Gregory Moe in Oakland, California.
Saccharo has raised $6.7M across 1 funding round on record, the most recent an undisclosed round of $6.7M announced in Aug 2022.
That round is below the $8.0M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Saccharo Company Profile and Key Stats
Latest funding round on record: Aug 2022.
Saccharo Funding Rounds
Saccharo Founders and Leadership Team
No contact details are on record for this team yet.
Saccharo Funding Compared to Other Biotechnology Startups
Saccharo's latest round of $6.7M is below the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Saccharo in Biotechnology and Oakland
Companies Similar to Saccharo
SeqWell’s is a biotechnology company that specializes in the fields of gene sequencing and laboratory…
DermaSensor’s mission is to save lives and healthcare costs by providing easy access to effective skin cancer…
Solstice Oncology is a clinical stage immuno-oncology company
Encoded Therapeutics is a developer of precision gene therapies intended to provide treatment for a broad…
BrainChild Bio is a biotechnology company in the clinical stage that specializes in pediatric brain tumors.…
Superluminal Medicines is a biotech company that specializes in rapidly developing new drugs through a…
Senticell's mission is to fully harness the unique immune and genetic functions of RBC to transform and treat…
ImmunoPhotonics, Inc. develops immunotherapy-based treatments for cancer. ImmunoPhotonics, Inc. has a…
EIT Pharma is a commercial-stage biotechnology company focuses on developing and commercializing…
Halia Therapeutics is a biopharmaceutical company in the preclinical stage that is developing new treatments…
Noveome Biotherapeutics, Inc. is an advanced biopharmaceutical company that focuses on groundbreaking…
XiltriX North America is an information technology company that specializes in monitoring, predictive…
Saccharo Funding FAQs
What does Saccharo do?
Saccharo is a biotech start-up in the immuno-oncology space that develops therapeutic products for the treatment of cancer and other novel diseases. Saccharo discovered a polysaccharide that surrounds human cancer cells. The Sacchario approach has a mechanism of action that allows drugs to have multiple killing effects, a predicted safety profile, a broad therapeutic window, and applications to many cancers. Saccharo was established in 2017 by Sherry Martin-Moe and Gregory Moe in Oakland, California.
How much funding has Saccharo raised?
Saccharo has raised $6.7M across 1 round on record. The most recent is an undisclosed round of $6.7M announced in Aug 2022.
When did Saccharo last raise funding?
Saccharo's most recent funding round on record is an undisclosed round of $6.7M, announced in Aug 2022.
Who founded Saccharo?
FundedIQ lists Sherry Martin Moe (Founder) at Saccharo.
Where is Saccharo headquartered?
Saccharo is based in Oakland, California, United States.
How many employees does Saccharo have?
Saccharo is in the 1-10 employee band.
How does Saccharo's funding compare to other Biotechnology startups?
Saccharo's latest round of $6.7M is below the $8.0M median round size for Biotechnology companies on FundedIQ across 4,183 tracked companies over the last two years.
About FundedIQ's Saccharo Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Saccharo is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Every newly funded startup with its round, its investors and its founders: delivered weekly by email, or searchable in the app.
Alerts from $19/mo · Pro from $99/mo. Card required, nothing charged until day 15, and we email you 3 days before that.